CHEK1 and glioblastoma: Western blot using CHK1-ser-317 phosphorylation as a basal DDR biomarker of ATR-activated CHK1 (ref. 29) showed that GBM patient-derived organoids (PDOs) classified as PPR5 exhibited higher levels of basal DDR/RS than GPM PDOs (Fig. 4d).